Figure 1.

ActRII inhibition enhances fat mass loss and preserves lean mass during weight loss induced by GLP-1 receptor agonism in obese mice.

A) Experimental schematic.

B) Change in total body weight (g) over 14 days.

C) Percent change in total body weight from baseline over 14 days.

D) Change in fat mass (g) determined by MRI at day 0, 7, and 13.

E) Percent change in fat mass from baseline at day 0, 7, and 13.

F) Change in lean mass (g) determined by MRI at day 0, 7, and 13.

G) Percent change in lean mass from baseline at day 0, 7, and 13.

H) Cumulative food intake over 12 days (n = 3 mice per group for days 1–4; n = 2 for control group (one mouse removed due to animal welfare complications) and n = 3 for semaglutide, bimagrumab, and semaglutide plus bimagrumab groups for days 5–12).

n = 8 mice for control and semaglutide + bimagrumab groups, n = 9 mice for semaglutide and bimagrumab groups unless otherwise indicated.∗p < 0.05, ∗∗p < 0.001, ∗∗∗p < 0.0005, ∗∗∗∗p < 0.0001 for control vs. bimagrumab, semaglutide, and semaglutide + bimagrumab; #p < 0.05, ##p < 0.001, ###p < 0.0005, ####p < 0.0001 for bimagrumab vs. semaglutide and semaglutide + bimagrumab; & p < 0.05, && p < 0.001 for semaglutide vs. semaglutide + bimagrumab.